Derm Cases · Dermatology / Therapeutics / Paediatrics
OSCE — prescribe topical calcineurin inhibitors: face/fold use, proactive therapy, and safety counselling
An 8-minute OSCE station on choosing tacrolimus/pimecrolimus for facial and flexural atopic dermatitis, steroid-sparing and proactive regimens, application counselling, infection precautions, and balanced discussion of the boxed malignancy warning.
On this page
Study tools
Target exams
NEET-PGINICETUSMLEPLABMRCP
Prompt
An 8-minute OSCE station on choosing tacrolimus/pimecrolimus for facial and flexural atopic dermatitis, steroid-sparing and proactive regimens, application counselling, infection precautions, and balanced discussion of the boxed malignancy warning.
Brief (to candidate)
A 9-year-old with eyelid and facial atopic eczema flares when topical steroids stop; parents fear steroid side-effects and ask about tacrolimus/pimecrolimus. No active eczema herpeticum. You have 8 minutes to prescribe a TCI correctly, counsel use and safety, and integrate with emollient/TCS plans.
[1]Candidate instructions
- Name tacrolimus 0.03%/0.1% and pimecrolimus 1% and typical site/severity roles.
- Prefer TCIs for face, eyelids, folds and discuss proactive maintenance.
- Counsel burning, infection precautions, and sun advice.
- Discuss the boxed warning with balanced evidence-based language.
- State when not to apply (active cutaneous viral infection).
Examiner checklist (mark each domain / 10)
| Domain | Key actions expected |
|---|---|
| Agents | Pimecrolimus 1% cream for mild–moderate AD; tacrolimus 0.03% (commonly children ≥2 y per label context) and 0.1% ointment for more stubborn facial/fold disease — topical calcineurin inhibition as steroid-sparing therapy[1][2] |
| Best indications/sites | Face, eyelids, neck, flexures, anogenital skin where chronic potent TCS risks atrophy and ocular steroid effects; useful after induction for proactive twice-weekly maintenance on frequently relapsing sites[2][3] |
| Technique | Thin layer to affected skin; often twice daily in flares then step down; continue emollients; may combine in a plan with body TCS for thick plaques |
| Adverse effects | Transient burning/stinging common initially; usually improves — counsel before first use |
| Infection precautions | Avoid on active HSV/eczema herpeticum or uncontrolled bacterial infection; seek care for fever with punched-out erosions[4] |
| Boxed warning | Malignancy warning historically applied; counsel risk–benefit and photoprotection without abandoning indicated therapy when benefits outweigh theoretical risks[5] |
| Communication | Written face/fold plan; address steroid phobia; review response in weeks |
Model key actions
- Prescribe TCI for facial/eyelid AD as steroid-sparing therapy with emollient backbone.[1][2]
- Counsel initial burning and avoid use on active herpetic skin.[4]
- Explain boxed warning in balanced terms and set proactive/flare plan.[5]
Common errors
- Applying TCI to active eczema herpeticum.
- Using fear of the boxed warning to leave severe facial disease untreated.
- No emollient plan.
- Wrong age/strength counselling without checking local label guidance.
- Expecting TCI alone to replace systemic therapy for erythrodermic disease.
References6ShowHide
- [1]Ohtsuki M, Morimoto H, Nakagawa H Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits. The Journal of dermatology, 2018.PMID 29927498
- [2]Devasenapathy N, Chu A, Wong M, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review. The Lancet. Child & adolescent health, 2023.PMID 36370744
- [3]Luger T, Chu CY, Elgendy A, et al. Pimecrolimus 1% cream for mild-to-moderate atopic dermatitis: a systematic review and meta-analysis with a focus on children. European journal of dermatology : EJD, 2023.PMID 38297923
- [4]Wu PC, Huang IH, Liu CW, et al. Topical calcineurin inhibitors and risk of lymphoma: a systematic review and meta-analysis. Journal der Deutschen Dermatologischen Gesellschaft, 2021.PMID 34390192
- [5]Dhar S, De A, Saha A, et al. Intermittent or Sequential Topical Tacrolimus in Atopic Dermatitis: Systematic Review and Meta-Analysis. Cureus, 2023.PMID 38229798
- [6]Alzahrani M, Kamal YF, Akram MA Tacrolimus Ointment in Periorbital Atopic Dermatitis. Cureus, 2024.PMID 38410340